{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,6]],"date-time":"2026-03-06T18:40:38Z","timestamp":1772822438153,"version":"3.50.1"},"reference-count":27,"publisher":"American Society of Clinical Oncology (ASCO)","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCO"],"published-print":{"date-parts":[[1999,3]]},"abstract":"<jats:p> PURPOSE: To determine the response rate, time to treatment failure, and toxicity of phenylacetate in patients with recurrent malignant glioma and to identify plasma concentrations achieved during repeated continuous infusion of this agent. <\/jats:p><jats:p> PATIENTS AND METHODS: Adult patients with recurrent malignant glioma were treated with phenylacetate. The schedule consisted of a 2-week continuous, intravenous infusion followed by a 2-week rest period (14 days on, 14 days off). A starting dose of 400 mg\/kg total body weight per day of phenylacetate was initially used and subsequently changed to 400 mg\/kg\/d based on ideal body weight. Intrapatient dose escalations were allowed to a maximum of 450 mg\/kg ideal body weight\/d. Tumor response was assessed every 8 weeks. The National Cancer Institute common toxicity criteria were used to assess toxicity. Plasma concentrations achieved during the patients' first two 14-day infusions were assessed. <\/jats:p><jats:p> RESULTS: Forty-three patients were enrolled between December 1994 and December 1996. Of these, 40 patients were assessable for toxicity and response to therapy. Reversible symptoms of fatigue and somnolence were the primary toxicities, with only mild hematologic toxicity. Thirty (75%) of the 40 patients failed treatment within 2 months, seven (17.5%) had stable disease, and three (7.5%) had a response defined as more than 50% reduction in the tumor. Median time to treatment failure was 2 months. Thirty-five patients have died, with a median survival of 8 months. Pharmacokinetic data for this dose schedule showed no difference in the mean plasma concentrations of phenylacetate between weeks 1 and 2 or between weeks 5 and 6. <\/jats:p><jats:p> CONCLUSION: Phenylacetate has little activity at this dose schedule in patients with recurrent malignant glioma. Further studies with this drug would necessitate an evaluation of a different dose schedule. <\/jats:p>","DOI":"10.1200\/jco.1999.17.3.984","type":"journal-article","created":{"date-parts":[[2017,2,24]],"date-time":"2017-02-24T09:58:08Z","timestamp":1487930288000},"page":"984-984","source":"Crossref","is-referenced-by-count":62,"title":["Phase II Study of Phenylacetate in Patients With Recurrent Malignant Glioma: A North American Brain Tumor Consortium Report"],"prefix":"10.1200","volume":"17","author":[{"given":"Susan M.","family":"Chang","sequence":"first","affiliation":[{"name":"From the University of California Medical Center, San Francisco, CA; University of Texas Health Science Center, Dallas, TX; University of Texas, South Western, Dallas, TX; University of Washington Medical Center, Seattle, WA; University of Wisconsin Comprehensive Cancer Center, Madison, WI; Montefiore University Hospital, Pittsburgh, PA; and Southwest Oncology Group Statistical Center, Seattle, WA."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John G.","family":"Kuhn","sequence":"additional","affiliation":[{"name":"From the University of California Medical Center, San Francisco, CA; University of Texas Health Science Center, Dallas, TX; University of Texas, South Western, Dallas, TX; University of Washington Medical Center, Seattle, WA; University of Wisconsin Comprehensive Cancer Center, Madison, WI; Montefiore University Hospital, Pittsburgh, PA; and Southwest Oncology Group Statistical Center, Seattle, WA."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"H. Ian","family":"Robins","sequence":"additional","affiliation":[{"name":"From the University of California Medical Center, San Francisco, CA; University of Texas Health Science Center, Dallas, TX; University of Texas, South Western, Dallas, TX; University of Washington Medical Center, Seattle, WA; University of Wisconsin Comprehensive Cancer Center, Madison, WI; Montefiore University Hospital, Pittsburgh, PA; and Southwest Oncology Group Statistical Center, Seattle, WA."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S. Clifford","family":"Schold","sequence":"additional","affiliation":[{"name":"From the University of California Medical Center, San Francisco, CA; University of Texas Health Science Center, Dallas, TX; University of Texas, South Western, Dallas, TX; University of Washington Medical Center, Seattle, WA; University of Wisconsin Comprehensive Cancer Center, Madison, WI; Montefiore University Hospital, Pittsburgh, PA; and Southwest Oncology Group Statistical Center, Seattle, WA."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexander M.","family":"Spence","sequence":"additional","affiliation":[{"name":"From the University of California Medical Center, San Francisco, CA; University of Texas Health Science Center, Dallas, TX; University of Texas, South Western, Dallas, TX; University of Washington Medical Center, Seattle, WA; University of Wisconsin Comprehensive Cancer Center, Madison, WI; Montefiore University Hospital, Pittsburgh, PA; and Southwest Oncology Group Statistical Center, Seattle, WA."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mitchel S.","family":"Berger","sequence":"additional","affiliation":[{"name":"From the University of California Medical Center, San Francisco, CA; University of Texas Health Science Center, Dallas, TX; University of Texas, South Western, Dallas, TX; University of Washington Medical Center, Seattle, WA; University of Wisconsin Comprehensive Cancer Center, Madison, WI; Montefiore University Hospital, Pittsburgh, PA; and Southwest Oncology Group Statistical Center, Seattle, WA."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Minesh P.","family":"Mehta","sequence":"additional","affiliation":[{"name":"From the University of California Medical Center, San Francisco, CA; University of Texas Health Science Center, Dallas, TX; University of Texas, South Western, Dallas, TX; University of Washington Medical Center, Seattle, WA; University of Wisconsin Comprehensive Cancer Center, Madison, WI; Montefiore University Hospital, Pittsburgh, PA; and Southwest Oncology Group Statistical Center, Seattle, WA."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael E.","family":"Bozik","sequence":"additional","affiliation":[{"name":"From the University of California Medical Center, San Francisco, CA; University of Texas Health Science Center, Dallas, TX; University of Texas, South Western, Dallas, TX; University of Washington Medical Center, Seattle, WA; University of Wisconsin Comprehensive Cancer Center, Madison, WI; Montefiore University Hospital, Pittsburgh, PA; and Southwest Oncology Group Statistical Center, Seattle, WA."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ian","family":"Pollack","sequence":"additional","affiliation":[{"name":"From the University of California Medical Center, San Francisco, CA; University of Texas Health Science Center, Dallas, TX; University of Texas, South Western, Dallas, TX; University of Washington Medical Center, Seattle, WA; University of Wisconsin Comprehensive Cancer Center, Madison, WI; Montefiore University Hospital, Pittsburgh, PA; and Southwest Oncology Group Statistical Center, Seattle, WA."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David","family":"Schiff","sequence":"additional","affiliation":[{"name":"From the University of California Medical Center, San Francisco, CA; University of Texas Health Science Center, Dallas, TX; University of Texas, South Western, Dallas, TX; University of Washington Medical Center, Seattle, WA; University of Wisconsin Comprehensive Cancer Center, Madison, WI; Montefiore University Hospital, Pittsburgh, PA; and Southwest Oncology Group Statistical Center, Seattle, WA."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mark","family":"Gilbert","sequence":"additional","affiliation":[{"name":"From the University of California Medical Center, San Francisco, CA; University of Texas Health Science Center, Dallas, TX; University of Texas, South Western, Dallas, TX; University of Washington Medical Center, Seattle, WA; University of Wisconsin Comprehensive Cancer Center, Madison, WI; Montefiore University Hospital, Pittsburgh, PA; and Southwest Oncology Group Statistical Center, Seattle, WA."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cathy","family":"Rankin","sequence":"additional","affiliation":[{"name":"From the University of California Medical Center, San Francisco, CA; University of Texas Health Science Center, Dallas, TX; University of Texas, South Western, Dallas, TX; University of Washington Medical Center, Seattle, WA; University of Wisconsin Comprehensive Cancer Center, Madison, WI; Montefiore University Hospital, Pittsburgh, PA; and Southwest Oncology Group Statistical Center, Seattle, WA."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael D.","family":"Prados","sequence":"additional","affiliation":[{"name":"From the University of California Medical Center, San Francisco, CA; University of Texas Health Science Center, Dallas, TX; University of Texas, South Western, Dallas, TX; University of Washington Medical Center, Seattle, WA; University of Wisconsin Comprehensive Cancer Center, Madison, WI; Montefiore University Hospital, Pittsburgh, PA; and Southwest Oncology Group Statistical Center, Seattle, WA."}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"233","reference":[{"key":"R1-0984","doi-asserted-by":"publisher","DOI":"10.1016\/0006-2952(95)02013-3"},{"key":"R2-0984","unstructured":"Samid  D,  Ram  Z,  Hudgins  WR, et al: Selective activity of phenylacetate against malignant gliomas: Resemblance to fetal brain damage in phenylketonuria.  Cancer Res 54:891,1994-895,"},{"key":"R3-0984","doi-asserted-by":"publisher","DOI":"10.3171\/jns.1995.83.4.0672"},{"key":"R4-0984","unstructured":"Ram  Z,  Samid  D,  Walbridge  S, et al: Growth inhibition, tumor maturation, and extended survival in experimental brain tumors in rats treated with phenylacetate.  Cancer Res 54:2934,1994-2927,"},{"key":"R5-0984","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM198406213102503"},{"key":"R6-0984","doi-asserted-by":"publisher","DOI":"10.1203\/00006450-198611000-00011"},{"key":"R7-0984","unstructured":"Mendenhall  CL,  Rouster  S,  Marshall  L, et al: A new therapy for portal systemic encephalopathy.  Am J Gastroenterol 81:540,1986-543,"},{"key":"R8-0984","doi-asserted-by":"crossref","unstructured":"Watson  AJ,  Karp  JE,  Walker  WG, et al: Transient idiopathic hyperammonaemia in adults.  Lancet 2:1271,1985-1274,","DOI":"10.1016\/S0140-6736(85)91554-5"},{"key":"R9-0984","doi-asserted-by":"publisher","DOI":"10.1098\/rspb.1972.0064"},{"key":"R10-0984","unstructured":"Weber  G: Biochemical strategy of cancer cells and the design of chemotherapy: GHA Clowes Memorial Lecture.  Cancer Res 43:3466,1983-3492,"},{"key":"R11-0984","unstructured":"Medina  MA,  Sanchez-Jimenez  F,  Marquez  FJ, et al: Glutamine and glucose as energy substrates for Ehrlich ascites tumor cells.  Biochem Int 16:339,1988-347,"},{"key":"R12-0984","unstructured":"Rosenfeld  H,  Roberts  J: Enhancement of antitumor activity of glutamine antagonists 6-diazo-5-oxo-l-norleucine and acivicin in cell culture by glutaminase-asparaginase.  Cancer Res 41:1324,1981-1328,"},{"key":"R13-0984","unstructured":"Gorospe  M,  Shack  S,  Guyton  KZ, et al: Up-regulation and functional role of p21during growth arrest of human breast carcinoma MCF-7 cells by phenylacetate.  Cell Growth Differ 7:1609,1996-1615, Waf1\/Cip1"},{"key":"R14-0984","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1097-0045(199609)29:3<177::AID-PROS3>3.0.CO;2-B"},{"key":"R15-0984","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-5347(01)66194-9"},{"key":"R16-0984","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.2910600414"},{"key":"R17-0984","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(19950615)75:12<2932::AID-CNCR2820751221>3.0.CO;2-P"},{"key":"R18-0984","unstructured":"Thibault  A,  Cooper  MR,  Figg  WD, et al: A phase I and pharmacokinetic study of intravenous phenylacetate in patients with cancer.  Cancer Res 54:1690,1994-1694,"},{"key":"R19-0984","doi-asserted-by":"crossref","unstructured":"Kaplan  EL,  Meier  P: Nonparametric estimation for incomplete observations.  J Am Stat Assoc 53:163,1958-170,","DOI":"10.1080\/01621459.1958.10501452"},{"key":"R20-0984","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.2910630122"},{"key":"R21-0984","unstructured":"Samid  D,  Shack  S,  Sherman  LT: Phenylacetate: A novel nontoxic inducer of tumor cell differentiation.  Cancer Res 52:1988,1992-1992,"},{"key":"R22-0984","doi-asserted-by":"crossref","unstructured":"Prasanna  P,  Thibault  A,  Liu  L, et al: Lipid metabolism as a target for brain cancer therapy: Synergistic activity of lovastatin and sodium phenylacetate against human glioma cells.  J Neurochem 66:710,1996-716,","DOI":"10.1046\/j.1471-4159.1996.66020710.x"},{"key":"R23-0984","unstructured":"Adam  L,  Crepin  M,  Savin  C, et al: Sodium phenylacetate induces growth inhibition and -2 down-regulation and apoptosis in MCF7ras cells in vitro and in nude mice.  Cancer Res 55:5156,1995-5160, Bcl"},{"key":"R24-0984","doi-asserted-by":"publisher","DOI":"10.1016\/0006-2952(96)00340-1"},{"key":"R25-0984","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp.45.4.366"},{"key":"R27-0984","doi-asserted-by":"publisher","DOI":"10.1080\/095530097143437"},{"key":"R28-0984","doi-asserted-by":"publisher","DOI":"10.1002\/j.1552-4604.1995.tb04075.x"}],"container-title":["Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ascopubs.org\/doi\/pdfdirect\/10.1200\/JCO.1999.17.3.984","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,5,25]],"date-time":"2022-05-25T22:15:00Z","timestamp":1653516900000},"score":1,"resource":{"primary":{"URL":"https:\/\/ascopubs.org\/doi\/10.1200\/JCO.1999.17.3.984"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1999,3]]},"references-count":27,"journal-issue":{"issue":"3","published-print":{"date-parts":[[1999,3]]}},"alternative-id":["10.1200\/JCO.1999.17.3.984"],"URL":"https:\/\/doi.org\/10.1200\/jco.1999.17.3.984","relation":{},"ISSN":["0732-183X","1527-7755"],"issn-type":[{"value":"0732-183X","type":"print"},{"value":"1527-7755","type":"electronic"}],"subject":[],"published":{"date-parts":[[1999,3]]}}}